GlassScriptPhysician profile
Cheyenne Taylor
NPI 1881432714
$1,111.29
in general payments reported to CMS, 2019-2025
16 companies · $705 in 2025
The $705 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $407 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $535.46 | 2024-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $123.99 | 2024 | Farxiga |
| Philips North America LLC | $78.68 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| E.R. Squibb & Sons, L.L.C. | $59.24 | 2024 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $56.53 | 2024-2025 | |
| Edwards Lifesciences Corporation | $36.72 | 2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $34.43 | 2024 | Verquvo |
| Pfizer INC. | $32.43 | 2024-2025 | |
| Novo Nordisk INC | $23.17 | 2025 | Wegovy |
| Cvrx, INC. | $22.00 | 2024 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $19.88 | 2025 | Opsumit |
| Janssen Pharmaceuticals, INC | $19.58 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $18.16 | 2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $17.92 | 2025 | |
| Boston Scientific Corporation | $17.58 | 2025 | Watchman Flx |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $15.52 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheyenne Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.